Videos

A panel of experts on prostate cancer discuss the role for fusion-guided biopsies in active surveillance for patients with prostate cancer.

Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.

“Maybe the most important [finding] is that urinary tumor DNA does seem to be a good tool for detecting residual disease within this patient population,” says Joshua Linscott, MD, PhD.

Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

“What was also interesting in our study was that when choosing a source of medications, we asked them, what made you decide to go with that option? And 62% of men said that they valued privacy above everything,” says Justin M. Dubin, MD.

“We've been developing different techniques in HoLEP, but there is a steep learning curve,” says Akhil Das, MD.

Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 AUA Annual Meeting.

"In 2015, we had 3 employed urologists in our health network. Now, we have 19 employed urologists in our health network," says Edward M. Schaeffer, MD, PhD.

"I think these findings are critical in helping us craft educational resources that would be easily understood and easily disseminated by trusted health care providers," says Stephanie Gleicher, MD, MPH.

"Our data showed that the patient regret scores were very, very low in looking at the patients that went home the same day," says David I. Lee, MD, FACS.

“The negative predictive value we want to be high, and the false positive rate we want to be low. None of those beat the radiologist reads in both of those categories,” says Robert S. Wang, MD.

"I think having success with that in humans will make [radiofrequency ablation] very, very valuable for the practicing urologist that can be done in the clinic without much training or anything like that," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"We have a nice organizational framework for us to really provide effective care that really feels the same throughout the different regions," says Edward M. Schaeffer, MD, PhD.

"Glean technology is a very brilliant technology that has been developed for basically portable urodynamics," says Zhina Sadeghi, MD.

“However, what direct to consumer does provide is convenience and privacy. Men's health has a huge stigma on it,” says Justin M. Dubin, MD.

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

The panel discusses how PSMA-PET imaging informs treatment decisions for patients with prostate cancer.

Focusing on the role of systematic biopsy, the panel provides clinical insights on biopsy practice patterns after encountering suspicious-looking areas on MRI.

Experts on prostate cancer focus on the differences between fusion-guided technologies, highlighting cognitive-based and software-based fusions.

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.

"We...found that about 50% of women felt like infections are caused by lack of cleanliness and tight-fitting clothes," says Stephanie Gleicher, MD.

“We may be tempted to conclude a causal relationship based on the results of this analysis; however, we should avoid making statements implying a causal relationship,” says Jaleh Fallah, MD.

Suzette E. Sutherland, MD, MS, FPMRS, recaps the 2024 AUA session, “Panel Discussion: Which Type of Sling Is Best in the Index SUI Patient?”

"With regards to barriers to attaining health information, we found that a lot of women reported that medical language is just too complex," says Stephanie Gleicher, MD, MPH.

Gary D. Steinberg, MD, analyzes data from the BOND-003 study presented at AUA 2024, which investigated the use of intravesical cretostimogene grenadenorepvec for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, and discusses the mechanism of action of this novel oncolytic viral therapy.

“Again, the importance of this paper to clinical practice is that it gives us real numbers on what the likelihood is of cancer in those patients with PI-RADS 3 or less,” says Jason M. Hafron, MD.